Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 4323 · Ensuring Access to Lower-Cost Medicines for Seniors Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

42 U.S.C. § 1395w–102 Prescription drug benefits

+4 −2Shown
More for 42 U.S.C. § 1395w–102
Read § 1395w–102Only this section
3 changes the bill asks for here, 3 carried out
  1. Carried out:

    in subparagraph (A), by striking and paragraphs (8) and (9) and inserting , paragraphs (8) and (9), and section 1860D–4(b)(3)(K); and

  2. Carried out:

    in subparagraph (B), by inserting before the period the following: and section 1860D–4(b)(3)(K); and

  3. Carried out:

    in subsection (c), by adding at the end the following new paragraph:(7) Treatment of cost-sharing for part D generic drugs and part D biosimilar biological products.— The coverage is provided in accordance with section 1860D–4(b)(3)(K)..

§ 1395w–102(b)Standard prescription drug coverage(1)–(2)

Start of § 1395w–102 to (b)(1)(A)(ii) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(1)(B)(B) Rounding(B) Rounding
Any amount determined under subparagraph (A)(ii) that is not a multiple of $5 shall be rounded to the nearest multiple of $5.Any amount determined under subparagraph (A)(ii) that is not a multiple of $5 shall be rounded to the nearest multiple of $5.
(2)(2) Benefit structure(2) Benefit structure
(2)(A)(A) 25 percent coinsurance(A) 25 percent coinsurance
Subject to subparagraphs (C), (D), and (E) [struck: and] paragraphs (8) and (9), the coverage has coinsurance (for costs above the annual deductible specified in paragraph (1) and up to the initial coverage limit under paragraph (3) for a year preceding 2025 and for costs above the annual deductible specified in paragraph (1) and up to the annual out-of-pocket threshold specified in paragraph (4)(B) for 2025 and each subsequent year) that is—Subject to subparagraphs (C), (D), and (E) [inserted: ,] paragraphs (8) and (9), [inserted: and section 1860D–4(b)(3)(K), ]the coverage has coinsurance (for costs above the annual deductible specified in paragraph (1) and up to the initial coverage limit under paragraph (3) for a year preceding 2025 and for costs above the annual deductible specified in paragraph (1) and up to the annual out-of-pocket threshold specified in paragraph (4)(B) for 2025 and each subsequent year) that is—
(2)(A)(i)(i) (i)
equal to 25 percent; orequal to 25 percent; or
(2)(A)(ii)(ii) (ii)
actuarially equivalent (using processes and methods established under section 1395w–111(c) of this title) to an average expected payment of 25 percent of such costs.actuarially equivalent (using processes and methods established under section 1395w–111(c) of this title) to an average expected payment of 25 percent of such costs.
(2)(B)(B) Use of tiers(B) Use of tiers
Nothing in this part shall be construed as preventing a PDP sponsor or an MA organization from applying tiered copayments under a plan, so long as such tiered copayments are consistent with subparagraphs (A)(ii), (C), and (D).Nothing in this part shall be construed as preventing a PDP sponsor or an MA organization from applying tiered copayments under a plan, so long as such tiered copayments are consistent with subparagraphs (A)(ii), (C), and (D)[inserted: and section 1860D–4(b)(3)(K)].
(2)(C)(C) Coverage for generic drugs in coverage gap(C) Coverage for generic drugs in coverage gap
(2)(C)(i)(i) In general(i) In general
Except as provided in paragraphs (4), (8), and (9), for a year preceding 2025, the coverage for an applicable beneficiary (as defined in section 1395w–114a(g)(1) of this title) has coinsurance (for costs above the initial coverage limit under paragraph (3) and below the out-of-pocket threshold) for covered part D drugs that are not applicable drugs under section 1395w–114a(g)(2) of this title that is—Except as provided in paragraphs (4), (8), and (9), for a year preceding 2025, the coverage for an applicable beneficiary (as defined in section 1395w–114a(g)(1) of this title) has coinsurance (for costs above the initial coverage limit under paragraph (3) and below the out-of-pocket threshold) for covered part D drugs that are not applicable drugs under section 1395w–114a(g)(2) of this title that is—

§ 1395w–102(c)–(d)

(b)(2)(C)(i)(I)–(c)(4) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(c)(5)(5) Treatment of cost-sharing for adult vaccines recommended by the Advisory Committee on Immunization Practices(5) Treatment of cost-sharing for adult vaccines recommended by the Advisory Committee on Immunization Practices
The coverage is in accordance with subsection (b)(8).The coverage is in accordance with subsection (b)(8).
(c)(6)(6) Treatment of cost-sharing for covered insulin products(6) Treatment of cost-sharing for covered insulin products
The coverage is provided in accordance with subsection (b)(9).The coverage is provided in accordance with subsection (b)(9).
(c)(7)(7) [inserted: Treatment of cost-sharing for part D generic drugs and part D biosimilar biological products.—]
[inserted: The coverage is provided in accordance with section 1860D–4(b)(3)(K).]
(d)(d) Access to negotiated prices(d) Access to negotiated prices
(d)(1)(1) Access(1) Access
(d)(1)(A)(A) In general(A) In general
Under qualified prescription drug coverage offered by a PDP sponsor offering a prescription drug plan or an MA organization offering an MA–PD plan, the sponsor or organization shall provide enrollees with access to negotiated prices used for payment for covered part D drugs, regardless of the fact that no benefits may be payable under the coverage with respect to such drugs because of the application of a deductible or other cost-sharing or, for a year preceding 2025, an initial coverage limit (described in subsection (b)(3)).Under qualified prescription drug coverage offered by a PDP sponsor offering a prescription drug plan or an MA organization offering an MA–PD plan, the sponsor or organization shall provide enrollees with access to negotiated prices used for payment for covered part D drugs, regardless of the fact that no benefits may be payable under the coverage with respect to such drugs because of the application of a deductible or other cost-sharing or, for a year preceding 2025, an initial coverage limit (described in subsection (b)(3)).

Rest of § 1395w–102 unchanged

42 U.S.C. § 1395w–104 Beneficiary protections for qualified prescription drug coverage

+59 −0Shown
More for 42 U.S.C. § 1395w–104
Read § 1395w–104Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 1860D–4(b)(3) of the Social Security Act (42 U.S.C. 1395w–104(b)(3)) is amended by adding at the end the following new subparagraphs:(J) Required inclusion of certain generic drugs and biosimilar biological products.— (i) In general.— Subject to the succeeding provisions of this subparagraph, with respect to a plan year beginning on or after January 1, 2028, the following rules shall apply: (I) If the …

§ 1395w–104(b)Access to covered part D drugs(3)–(4)

Start of § 1395w–104 to (b)(3)(I) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(3)(I)(i)(i) In general(i) In general
For 2026 and each subsequent year, the PDP sponsor offering a prescription drug plan shall include each covered part D drug that is a selected drug under section 1320f–1 of this title for which a maximum fair price (as defined in section 1320f(c)(3) of this title) is in effect with respect to the year.For 2026 and each subsequent year, the PDP sponsor offering a prescription drug plan shall include each covered part D drug that is a selected drug under section 1320f–1 of this title for which a maximum fair price (as defined in section 1320f(c)(3) of this title) is in effect with respect to the year.
(3)(I)(ii)(ii) Clarification(ii) Clarification
Nothing in clause (i) shall be construed as prohibiting a PDP sponsor from removing such a selected drug from a formulary if such removal would be permitted under section 423.120(b)(5)(iv) of title 42, Code of Federal Regulations (or any successor regulation).Nothing in clause (i) shall be construed as prohibiting a PDP sponsor from removing such a selected drug from a formulary if such removal would be permitted under section 423.120(b)(5)(iv) of title 42, Code of Federal Regulations (or any successor regulation).
(3)(J)(J) [inserted: Required inclusion of certain generic drugs and biosimilar biological products.—]
(3)(J)(i)(i) [inserted: In general.—]
[inserted: Subject to the succeeding provisions of this subparagraph, with respect to a plan year beginning on or after January 1, 2028, the following rules shall apply:]
(3)(J)(i)(I)(I) [inserted: ]
[inserted: If the formulary includes a part D reference drug, the formulary shall include each part D generic drug of such part D reference drug for which the wholesale acquisition cost is less than the wholesale acquisition cost of such part D reference drug.]
(3)(J)(i)(II)(II) [inserted: ]
[inserted: If the formulary includes a part D reference biological product, the formulary shall include at least one part D biosimilar biological of such part D reference biological product for which the wholesale acquisition cost is less than the wholesale acquisition cost of such part D reference biological product (if one or more such part D biosimilar biologicals is available).]
(3)(J)(ii)(ii) [inserted: Determinations and implementation.—]
[inserted: Determinations of part D generic drugs and part D biosimilar biological products described in subclauses (I) and (II) of clause (i) and implementation of formulary requirements under clause (i) shall be made by PDP sponsors offering prescription drug plans in accordance with uniform requirements established by the Secretary (by program instruction or otherwise), which shall provide for such determinations to be made as of specified dates (in the case of determinations during a plan year, on a quarterly basis), and for any associated formulary changes to be implemented promptly thereafter (in accordance with timeframes specified by the Secretary). Such uniform requirements shall also specify circumstances under which a part D generic drug or part D biosimilar biological product shall be deemed for purposes of subclauses (I) and (II) of clause (i) to have a lower wholesale acquisition cost than its part D reference drug or part D reference biological product (so as to require its inclusion on formularies), including where no wholesale acquisition cost is published for such part D reference drug or part D reference biological product or the part D reference drug or part D reference biological product is not available for purchase by the PDP sponsor (or its network pharmacies) from its manufacturer at the published wholesale acquisition cost.]
(3)(J)(iii)(iii) [inserted: Prohibition on certain limits on access.—]
[inserted: The PDP sponsor offering the prescription drug plan may not impose limits on access to a part D generic drug required to be included on the formulary under clause (i)(I) or a part D biosimilar biological product required to be included on the formulary under clause (i)(II), including through prior authorization, utilization management, or step therapy, that are more restrictive than any such limits imposed on access to the part D reference drug of such part D generic drug or part D reference biological product of such part D biosimilar biological product, respectively, or that otherwise have the effect of giving preferred status to such part D reference drug or part D reference biological product over such part D generic drug or part D biosimilar biological product, respectively.]
(3)(J)(iv)(iv) [inserted: Definitions.—]
[inserted: In this subparagraph and subparagraph (K):]
(3)(J)(iv)(I)(I) [inserted: Part D biosimilar biological product.—]
[inserted: The term “part D biosimilar biological product” means a covered part D drug that is a biosimilar biological product (as defined in section 1847A(c)(6)(H)).]
(3)(J)(iv)(II)(II) [inserted: Part D generic drug.—]
[inserted: The term “part D generic drug” means a covered part D drug that is approved under section 505(j) of the Federal Food, Drug, and Cosmetic Act.]
(3)(J)(iv)(III)(III) [inserted: Part D reference biological product.—]
[inserted: The term “part D reference biological product” means a covered part D drug that is a reference biological product (as defined in section 1847A(c)(6)(I)).]
(3)(J)(iv)(IV)(IV) [inserted: Part D reference drug.—]
[inserted: The term “part D reference drug” means, with respect to a part D generic drug, a covered part D drug that is the listed drug (as described in clause (i) of section 505(j)(2)(A) of the Federal Food, Drug, and Cosmetic Act) that is referred to in the abbreviated application for such part D generic drug under such section.]
(3)(J)(iv)(V)(V) [inserted: Wholesale acquisition cost.—]
[inserted: The term “wholesale acquisition cost” has the meaning given such term in section 1847A(c)(6)(B).]
(3)(K)(K) [inserted: Cost-Sharing tiering requirements with respect to part D generic drugs and part D biosimilar biological products.—]
(3)(K)(i)(i) [inserted: Generic drug and biosimilar biological product cost-sharing tier.—]
[inserted: With respect to a plan year beginning on or after January 1, 2028, if the PDP sponsor offering the prescription drug plan applies tiered cost-sharing (through copayment or coinsurance tiers) to covered part D drugs on a formulary, the PDP sponsor shall—]
(3)(K)(i)(I)(I) [inserted: ]
[inserted: have at least one cost-sharing tier on the formulary that only includes part D generic drugs and part D biosimilar biological products; and]
(3)(K)(i)(II)(II) [inserted: ]
[inserted: with respect to each cost-sharing tier described in subclause (I) on the formulary, either apply no cost-sharing requirement or a copayment that is—]
(3)(K)(i)(II)(aa)(aa) [inserted: ]
[inserted: in the case where the lowest branded drug tier of such formulary bases cost-sharing on a copayment amount, an amount at least $20 lower than the copayment for such lowest branded drug tier (but in no case may such copayment amount be less than zero); or]
(3)(K)(i)(II)(bb)(bb) [inserted: ]
[inserted: in the case where the lowest branded drug tier of such formulary bases cost-sharing on a coinsurance percentage, an amount at least $20 lower than the actuarially expected average cost-sharing amount payable for the covered part D drugs included on such lowest branded drug tier, determined using processes and methods established under section 1860D–11(c) (but in no case may such copayment amount be less than zero).]
(3)(K)(ii)(ii) [inserted: Specialty generic drug and biosimilar biological product cost-sharing tier.—]
[inserted: With respect to a plan year beginning on or after January 1, 2028, if the PDP sponsor offering the prescription drug plan has a specialty tier, the PDP sponsor shall—]
(3)(K)(ii)(I)(I) [inserted: ]
[inserted: have a second specialty tier on such formulary that only includes part D generic drugs and part D biosimilar biological products—]
(3)(K)(ii)(I)(aa)(aa) [inserted: ]
[inserted: for which the cost (as defined by the Secretary) is greater than a cost threshold specified by the Secretary; and]
(3)(K)(ii)(I)(bb)(bb) [inserted: ]
[inserted: with respect to which the part D reference drug for such a part D generic drug or the part D reference biological product for such a part D biosimilar biological product is either included on a cost-sharing tier on such formulary with a cost-sharing requirement that is greater than the cost-sharing requirement applied under subclause (II), or excluded from such formulary; and]
(3)(K)(ii)(II)(II) [inserted: ]
[inserted: apply a coinsurance cost-sharing requirement with respect to the cost-sharing tier required for the formulary under subclause (I) that is at least 5 percentage points lower than the coinsurance percentage applicable to any other specialty tier of the formulary.]
(3)(K)(iii)(iii) [inserted: Placement of certain generic drugs and biosimilar biological products.—]
[inserted: Each part D generic drug and each part D biosimilar biological product required to be included on the formulary under subparagraph (J)(i) shall be included either on a cost-sharing tier described in clause (i)(I) or, if applicable, the cost-sharing tier required for the formulary under clause (ii)(I).]
(3)(K)(iv)(iv) [inserted: Application.—]
(3)(K)(iv)(I)(I) [inserted: In general.—]
[inserted: The requirements under clauses (i) through (iii) shall, subject to the requirements under section 1860D–14, apply after the individual has satisfied any deductible under subsections (a)(2)(A)(i) or (b)(1) of section 1860D–2.]
(3)(K)(iv)(II)(II) [inserted: Limitation.—]
[inserted: The Secretary shall not approve any benefit design for a prescription drug plan or an MA–PD plan to which the requirements of this subparagraph apply if such benefit design has any deductible applicable to any part D generic drug or part D biosimilar biological product unless such deductible, or a greater deductible, also applies to all other covered part D drugs on the formulary of such plan (subject to the requirements under section 1860D–14), except for lesser or zero deductibles applicable only to particular types of covered part D drugs which the Secretary determines warrant favorable cost-sharing when such lesser or zero deductibles are also applicable to part D generic drugs and part D biosimilar biological products of the given type.]
(3)(K)(v)(v) [inserted: Definitions.—]
[inserted: In this subparagraph:]
(3)(K)(v)(I)(I) [inserted: Brand drug.—]
[inserted: The term “brand drug” means a covered part D drug that is approved under section 505(c) of the Federal Food, Drug, and Cosmetic Act or licensed under section 351(a) of the Public Health Service Act.]
(3)(K)(v)(II)(II) [inserted: Lowest branded drug tier.—]
[inserted: The term “lowest branded drug tier” means the cost-sharing tier of a formulary which includes at least 1 brand drug and provides for the lowest level of cost sharing applicable to any such tier, as determined by the Secretary.]
(3)(K)(v)(III)(III) [inserted: Specialty tier.—]
[inserted: The term “specialty tier” means a cost-sharing tier consisting only of covered part D drugs that have a cost (as defined by the Secretary) which equals or exceeds an applicable cost threshold established by the Secretary for high-cost covered part D drugs to be eligible for inclusion on such cost-sharing tier.]
(4)(4) Ensuring access during COVID–19 public health emergency period(4) Ensuring access during COVID–19 public health emergency period
(4)(A)(A) In general(A) In general
During the emergency period described in section 1320b–5(g)(1)(B) of this title, subject to subparagraph (B), a prescription drug plan or MA–PD plan shall, notwithstanding any cost and utilization management, medication therapy management, or other such programs under this part, permit a part D eligible individual enrolled in such plan to obtain in a single fill or refill, at the option of such individual, the total day supply (not to exceed a 90-day supply) prescribed for such individual for a covered part D drug.During the emergency period described in section 1320b–5(g)(1)(B) of this title, subject to subparagraph (B), a prescription drug plan or MA–PD plan shall, notwithstanding any cost and utilization management, medication therapy management, or other such programs under this part, permit a part D eligible individual enrolled in such plan to obtain in a single fill or refill, at the option of such individual, the total day supply (not to exceed a 90-day supply) prescribed for such individual for a covered part D drug.

Rest of § 1395w–104 unchanged

Step through the changes